Lymphoma combo therapy trial ends early
Disease control
Terminated
This study tested a combination of two drugs, pembrolizumab and CMP-001, in 14 adults with lymphoma that had returned or stopped responding to prior treatments. The goal was to find a safe and effective dose to shrink tumors. The trial was terminated early, so results are limited…
Phase: PHASE1, PHASE2 • Sponsor: Umar Farooq • Aim: Disease control
Last updated May 08, 2026 12:04 UTC